TOP TEN perturbations for 39331_at (Homo sapiens)
Organism: Homo sapiens
Gene: 39331_at
Selected probe(set): 204141_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of 39331_at (204141_at) across 6674 perturbations tested by GENEVESTIGATOR:
dendritic cell study 6 (gardiquimod) / dendritic cell study 6 (untreated)
Relative Expression (log2-ratio):5.779477Number of Samples:7 / 8
| Experimental | dendritic cell study 6 (gardiquimod) |
| Plasmacytoid dendritic cells (pDCs) collected from blood of healthy donors and treated with gardiquimod (TLR7 agonist) for 3 hours. pDCs were sorted as CD303+, CD123+, CD45+, CD69+, CD40+, CD86+. | |
| Control | dendritic cell study 6 (untreated) |
| Plasmacytoid dendritic cells (pDCs) collected from blood of healthy donors. pDCs were sorted as CD303+, CD123+, CD45+, CD69+, CD40+, CD86+. |
dendritic cell study 6 (gardiquimod; RN486) / dendritic cell study 6 (untreated)
Relative Expression (log2-ratio):5.55602Number of Samples:4 / 8
| Experimental | dendritic cell study 6 (gardiquimod; RN486) |
| Plasmacytoid dendritic cells (pDCs) collected from blood of healthy donors and treated with gardiquimod (TLR7 agonist) and RN486 (Bruton’s tyrosine kinase; BTK inhibitor) for 3 hours. pDCs were sorted as CD303+, CD123+, CD45+, CD69+, CD40+, CD86+. | |
| Control | dendritic cell study 6 (untreated) |
| Plasmacytoid dendritic cells (pDCs) collected from blood of healthy donors. pDCs were sorted as CD303+, CD123+, CD45+, CD69+, CD40+, CD86+. |
dendritic cell study 6 (gardiquimod; RN486) / dendritic cell study 6 (CpG A; RN486)
Relative Expression (log2-ratio):4.9584303Number of Samples:4 / 4
| Experimental | dendritic cell study 6 (gardiquimod; RN486) |
| Plasmacytoid dendritic cells (pDCs) collected from blood of healthy donors and treated with gardiquimod (TLR7 agonist) and RN486 (Bruton’s tyrosine kinase; BTK inhibitor) for 3 hours. pDCs were sorted as CD303+, CD123+, CD45+, CD69+, CD40+, CD86+. | |
| Control | dendritic cell study 6 (CpG A; RN486) |
| Plasmacytoid dendritic cells (pDCs) collected from blood of healthy donors and treated with CpG-A ODN2216 Class A (TLR9 agonist) and RN486 (Bruton’s tyrosine kinase; BTK inhibitor) for 3 hours. pDCs were sorted as CD303+, CD123+, CD45+, CD69+, CD40+, CD86+. |
PMA; ionomycine study 2 / unstimulated CD4 memory T-cell sample
Relative Expression (log2-ratio):4.5539503Number of Samples:8 / 8
| Experimental | PMA; ionomycine study 2 |
| CD4+ memory T cells derived from peripheral blood of healthy subjects were stimulated for 3 hours with phorbol 12-myristate 13-acetate (PMA, 10 ng/ml) and ionomycin (1 µg/ml). ATC code:--- | |
| Control | unstimulated CD4 memory T-cell sample |
| Unstimulated CD4+ memory T cells derived from peripheral blood of healthy subjects. |
B-CLL study 11 (DMSO) / vehicle (DMSO) treated normal B-cell sample
Relative Expression (log2-ratio):-4.36051Number of Samples:4 / 4
| Experimental | B-CLL study 11 (DMSO) |
| Peripheral blood mononuclear cells (PBMCs) obtained from chronic lymphocytic leukemia (CLL) patients and in vitro treated with vehicle (DMSO) for 4 hours. PBMCs’ samples contained 90% CD19+ CD5+ B lineage CLL cells (B-CLL). Inclusion criteria: untreated CLL patients or at least 1 month after chemotherapy. Exclusion criteria: patients with active infections or other serious medical conditions or with white blood cell (WBC) counts of 15,000/l. | |
| Control | vehicle (DMSO) treated normal B-cell sample |
| MACS purified resting B-cells from healthy donor peripheral blood treated with vehicle (DMSO) for 4 hours. |
LPS study 2 / untreated THP-1 cell sample
Relative Expression (log2-ratio):4.180443Number of Samples:3 / 3
| Experimental | LPS study 2 |
| Cultured THP-1 mononuclear cells were treated with lipopolysaccharide (1 microgram/ml) for 4 hours at 37°C. ATC code:--- | |
| Control | untreated THP-1 cell sample |
| Cultured THP-1 mononuclear cells were cultured in basal growth media at 37°C. |
CAR T cell study 4 (GFP; post-infusion) / CAR T cell study 4 (GFP; pre-infusion)
Relative Expression (log2-ratio):3.9351501Number of Samples:3 / 3
| Experimental | CAR T cell study 4 (GFP; post-infusion) |
| CD8+ T cells transduced with GFP and isolated 30 days after adoptive transfer into mice bearing HPAC-derived pancreatic tumor. Human peripheral blood mononuclear cells were stimulated with anti-CD3 antibody (OKT3) in presence of IL-2. Two days post-stimulation, T cells were transduced with retroviral vectors encoding GFP as a control. Cells were cultured for 2 weeks in presence of IL-2 and then transfered into 4-5-week-old male NSG mice. Subcutaneous xenografts were generated by injection of HPAC cells. Once tumors became palpable, mice were treated with CD8+ T cells expressing GFP (control group). Untransduced CD4+ cells from the same donor were given to each mouse for cytokine support. Spleen-resident human CD8+ T cells were isolated 30 days later using the CD8 MicroBeads (post-infusion samples). | |
| Control | CAR T cell study 4 (GFP; pre-infusion) |
| Primary human CD8+ T cells stimulated ex vivo and transduced to express GFP. Human peripheral blood mononuclear cells were stimulated with anti-CD3 antibody (OKT3) in presence of IL-2. Two days post-stimulation, T cells were transduced with retroviral vectors encoding GFP as a control. Cells were cultured for 2 weeks in presence of IL-2, until collection of samples (pre-infusion samples). |
B-CLL study 11 (rolipram) / rolipram study 4 (normal B-cell; 20uM)
Relative Expression (log2-ratio):-3.8775072Number of Samples:4 / 4
| Experimental | B-CLL study 11 (rolipram) |
| Peripheral blood mononuclear cells (PBMCs) obtained from chronic lymphocytic leukemia (CLL) patients and in vitro treated with rolipram (20 uM, cyclic nucleotide phosphodiesterase (PDE4) inhibitor) for 4 hours. PBMCs’ samples contained 90% CD19+ CD5+ B lineage CLL cells (B-CLL). Inclusion criteria: untreated CLL patients or at least 1 month after chemotherapy. Exclusion criteria: patients with active infections or other serious medical conditions or with white blood cell (WBC) counts of 15,000/l. ATC code:--- | |
| Control | rolipram study 4 (normal B-cell; 20uM) |
| MACS purified resting B-cells from healthy donor peripheral blood treated with rolipram (20 uM, cyclic nucleotide phosphodiesterase (PDE4) inhibitor) for 4 hours. ATC code:--- |
ovarian tumor study 30 (PDX; clear cell adenocarcinoma, NOS; primary) / ovarian tumor study 30 (PDX; adenocarcinoma, NOS; primary)
Relative Expression (log2-ratio):-3.861268Number of Samples:2 / 2
| Experimental | ovarian tumor study 30 (PDX; clear cell adenocarcinoma, NOS; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary clear cell adenocarcinoma, NOS of the ovary (subcutaneously implanted). | |
| Control | ovarian tumor study 30 (PDX; adenocarcinoma, NOS; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary adenocarcinoma, NOS of the ovary (subcutaneously implanted). |
Langerhans cell histiocytosis study 1 / normal plasmocytoid dendritic cell sample
Relative Expression (log2-ratio):3.8561964Number of Samples:7 / 3
| Experimental | Langerhans cell histiocytosis study 1 |
| Langerhans cell histiocytes (LCH) were isolated from LCH lesions of patients undergoing surgery. All patients had single system disease, five patients had bone lesion, one had skin lesion and one had mucosal manifestation. Langerhans cells histiocytes were purified by FACS as CD1a+ / CD270 + population with > 95% purity. | |
| Control | normal plasmocytoid dendritic cell sample |
| Normal plasmocytoid dendritic cells were isolated from peripheral blood of healthy adult donors. Plasmocytoid dendritic cells were defined as HLA-DR+ / CD45RAhi / CD11c- / BDCA2+ population. |